Quick Answer
Ernexa Therapeutics Inc. reported Cash and Equivalents of $1.73 million for fiscal year 2024.
Ernexa Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $1.73M | -77.2% |
| 2023 | $7.58M | -33.8% |
| 2022 | $11.45M | -32.6% |
| 2021 | $16.98M | +2086.0% |
| 2020 | $777.0K | -75.8% |
| 2019 | $3.21M | +26.5% |
| 2018 | $2.54M | -24.9% |
| 2017 | $3.38M | -40.6% |
| 2016 | $5.69M | +76.4% |
| 2015 | $3.22M | -55.1% |
| 2014 | $7.18M | +31.7% |
| 2013 | $5.46M | +100.5% |
| 2012 | $2.72M | +98.0% |
| 2011 | $1.37M | -64.8% |
| 2010 | $3.91M | +7.4% |
| 2009 | $3.64M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $4.32M | +66.9% | +125.0% |
| March 31, 2025 | $1.92M | -62.5% | -55.0% |
| September 30, 2024 | $4.26M | -6.3% | +64.9% |
| June 30, 2024 | $2.59M | +40.8% | -49.5% |
| March 31, 2024 | $5.12M | -5.2% | +12.4% |
| September 30, 2023 | $4.55M | -65.7% | +147.7% |
| June 30, 2023 | $1.84M | -90.5% | -66.0% |
| March 31, 2023 | $5.40M | -77.0% | -59.3% |
- Ernexa Therapeutics Inc. showed a decrease of -77.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2024 period, Ernexa Therapeutics Inc.’s cash and equivalents has declined by 52.5% (from $3.64 million to $1.73 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 12, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: